2 results
Approved WMOWill not start
The purpose of this study is to evaluate the possible risks and efficacy (improvement of disease) with an experimental oral study drug named eliglustat in pediatric patients from 2 to 18 years with Gaucher disease.
Approved WMORecruiting
The aim of this global Phase III study is to investigate the use of tezepelumab as a treatment for patients with EoE. This study will evaluate the efficacy and safety of tezepelumab 210 mg every 4 weeks (Q4W) and tezepelumab 420mg Q4W administered…